Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Podobne knjige/članki

• Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
  od: Hjorth-Hansen, Henrik, et al.
  Izdano: (2015)
• Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (<scp>N</scp>ord<scp>CML</scp>006)
  od: Henrik Hjorth‐Hansen, et al.
  Izdano: (2014)
• Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
  od: Henrik Hjorth‐Hansen, et al.
  Izdano: (2016)
• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
  od: Mette Ilander, et al.
  Izdano: (2016)
• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
  od: Ilander, M, et al.
  Izdano: (2017)